ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1944

Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre

Arturo Llobell1, Belén Atienza-Mateo2, David Iturbe-Fernández3, Victor Mora-Cuesta3, Marcos Lopez-Hoyos4, Jose Cifrian5 and Ricardo Blanco6, 1Parc Tauli University Hospital, Barcelona, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, 4Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, 5Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) comprises a wide range of disorders categorized by clinical, radiographic and pathologic findings that is closely associated with autoimmune connective tissue diseases (CTD), requiring an investigation into a potential unknown CTD when diagnosing ILD. A significant number of patients can exhibit nonspecific signs of autoimmunity, either clinical and/or serologic, without meeting the criteria for a distinct CTD, which has led to the classification of this disease as Interstitial Pneumonia with Autoimmune Features (IPAF). In our study, we aim to characterize a cohort of patients with ILD who satisfy the IPAF criteria.

Methods: We collected data of patients assessed in a multidisciplinary clinic of Pneumology and Rheumatology at the Marqués de Valdecilla University Hospital (Santander, Spain). Included patients had a confirmed diagnosis of ILD, determined either through a chest high-resolution computed tomography (HRCT) or lung biopsy. Medical records were examined to assess clinical and/or serologic IPAF criteria, as well as HRCT and lung biopsy reports. Exclusion from the study took place if patients met classification criteria for a distinct CTD or if there was incomplete data to asses their case.

Results: From a cohort of 689 patients with ILD, we included a total of 34 individuals who fulfilled the criteria for IPAF. Among them, mean age at diagnosis was 58 ±11,84. 22 (65%) were male and 12 (35%) female. 27 (79%) had smoking history. 15 out of the 34 patients (44%) met the clinical criteria for IPAF, being Raynaud’s phenomenon the most frequent (n=10), followed by inflammatory arthritis (n=8), digital edema (n=2) and digital ulceration (n=1). Serologic criteria for IPAF were fulfilled by 28 out of 34 patients (84%). The most prevalent serologic criterion was the presence of an ANA higher than 1:320 (patterns: speckled, homogeneous or combined. n=17) followed by positive rheumatoid factor (n=6), anti-CCP (n=3), anti-ß2 glicoprotein (n=3), anti-DNA (n=2), anti-Ssa (n=2), anti-Ku (n=2) and anti-Ro52 (n=1). As for radiologic and morphologic criteria, 30 patients (88%) met the requirements for IPAF, being usual interstitial pneumonia (UIP) (n=11) the most frequently observed, followed by probable UIP pattern (n=7) and non-specific interstitial pneumonia (NSIP) (n=8). Table 1 shows the demographic, clinical, serologic and morphologic features of our patients.

Conclusion: This is a single-center, retrospective study focused on patients who fulfilled IPAF criteria. Among this cohort, a majority of men was reported (65%), and a high proportion of patients presented smoking history (79%). Regarding clinical, serologic or morphologic features, even with less than half of the patients (44%) showing clinical features of CTD, serologic (84%) and radiologic-morphologic (88%) criteria were met by a majority of patients. Given the benefits of early immunosuppressive treatment in this disease, a thorough identification of findings in either clinical, serologic and/or morphologic domains must be prioritized when approaching patients when suspecting a IPAF diagnosis.

Supporting image 1

Table 1. Demographic, clinical, serologic and morphologic features of 34 patients with IPAF.


Disclosures: A. Llobell: None; B. Atienza-Mateo: None; D. Iturbe-Fernández: None; V. Mora-Cuesta: None; M. Lopez-Hoyos: None; J. Cifrian: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Llobell A, Atienza-Mateo B, Iturbe-Fernández D, Mora-Cuesta V, Lopez-Hoyos M, Cifrian J, Blanco R. Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/characterization-of-interstitial-pneumonia-with-autoimmune-features-ipaf-in-a-national-referral-centre/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-interstitial-pneumonia-with-autoimmune-features-ipaf-in-a-national-referral-centre/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology